3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
718
Lung Neoplasms
310
Small Cell Lung Carcinoma
111
Neoplasms
42
Adenocarcinoma of Lung
40
Neoplasm Metastasis
35
Parkinson Disease 4, Autosomal Dominant Lewy Body
22
Brain Neoplasms
21
Carcinoma
19
Breast Neoplasms
18
Lung Diseases
15
NSCLC
14
Mesothelioma, Malignant
14
Thoracic Neoplasms
13
Adenocarcinoma, Bronchiolo-Alveolar
13
Prostatic Neoplasms
11
Pleural Effusion, Malignant
10
Non-Squamous Non-Small Cell Lung Cancer
10
Mesothelioma
10
Cachexia
10
Respiratory Tract Neoplasms
9
Pain
9
Bronchial Neoplasms
9
Respiratory Tract Diseases
8
Carcinoma, Squamous Cell
8
Carcinoma, Bronchogenic
8
Adenocarcinoma
8
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Colonic Neoplasms
7
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA